(Q53078951)

11 May 2018

title

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. (English)

1 reference

11 May 2018

relapsing-remitting multiple sclerosis

main subject

0 references

0 references

1

1 reference

11 May 2018

Dana Horáková

2

1 reference

11 May 2018

Vilija Jokubaitis

4

1 reference

11 May 2018

Maria Trojano

5

1 reference

11 May 2018

Alessandra Lugaresi

6

1 reference

11 May 2018

Eugenio Pucci

13

1 reference

11 May 2018

Mark Slee

15

1 reference

11 May 2018

Suzanne J. Hodgkinson

20

1 reference

11 May 2018

Helmut Butzkueven

33

1 reference

11 May 2018

Eva Havrdová

Eva Havrdova

32

0 references

Roberto Bergamaschi

25

Roberto Bergamaschi

1 reference

11 May 2018

Guillermo Izquierdo

7

Guillermo Izquierdo

1 reference

11 May 2018

Pierre Duquette

11

Pierre Duquette

1 reference

11 May 2018

Pamela A. McCombe

26

Pamela McCombe

1 reference

11 May 2018

Pierre Grammond

9

Pierre Grammond

1 reference

11 May 2018

Michael Barnett

23

Michael Barnett

1 reference

11 May 2018

Raed Alroughani

10

Raed Alroughani

1 reference

11 May 2018

author name string

Tim Spelman

3

1 reference

11 May 2018

Csilla Rozsa

8

1 reference

11 May 2018

Marc Girard

12

1 reference

11 May 2018

Jeannette Lechner-Scott

14

1 reference

11 May 2018

Ricardo Fernandez-Bolanos

16

1 reference

11 May 2018

Francois Grand'Maison

17

1 reference

11 May 2018

Raymond Hupperts

18

1 reference

11 May 2018

Freek Verheul

19

1 reference

11 May 2018

Celia Oreja-Guevara

21

1 reference

11 May 2018

Daniele Spitaleri

22

1 reference

11 May 2018

Murat Terzi

24

1 reference

11 May 2018

Jose Sanchez-Menoyo

27

1 reference

11 May 2018

Magdolna Simo

28

1 reference

11 May 2018

Tunde Csepany

29

1 reference

11 May 2018

Gabor Rum

30

1 reference

11 May 2018

Cavit Boz

31

1 reference

11 May 2018

MSBase Study Group

34

1 reference

11 May 2018

publication date

17 January 2015

1 reference

11 May 2018

published in

Annals of Neurology

1 reference

11 May 2018

volume

77

1 reference

11 May 2018

issue

3

1 reference

11 May 2018

page(s)

425-435

1 reference

11 May 2018

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS

cites work

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

Freedom from disease activity in multiple sclerosis

21 January 2018

1 reference

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

21 January 2018

1 reference

Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy

21 January 2018

1 reference

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

21 January 2018

1 reference

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis

21 January 2018

1 reference

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.

21 January 2018

1 reference

Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

21 January 2018

1 reference

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Sensitivity analysis after multiple imputation under missing at random: a weighting approach

21 January 2018

1 reference

Practical considerations for sensitivity analysis after multiple imputation applied to epidemiological studies with incomplete data

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

21 January 2018

1 reference

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

Fingolimod after natalizumab and the risk of short-term relapse

21 January 2018

1 reference

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

21 January 2018

1 reference

Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference

21 January 2018

1 reference

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.24339

1 reference

11 May 2018

PubMed ID

25546031

1 reference

11 May 2018